A novel class of photo-triggerable liposomes containing DPPC:DC8,9PC as vehicles for delivery of doxorubcin to cells  by Yavlovich, Amichai et al.
Biochimica et Biophysica Acta 1808 (2011) 117–126
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamemA novel class of photo-triggerable liposomes containing DPPC:DC8,9PC as vehicles for
delivery of doxorubcin to cells
Amichai Yavlovich a, Alok Singh b, Robert Blumenthal a, Anu Puri a,⁎
a Membrane Structure and Function Section, Nanobiology Program, NCI-Frederick, Frederick, MD 21702, USA
b Center for Bio/Molecular Science and Engineering, Naval Research Laboratory, Washington, D.C., USAAbbreviations: DPPC, 1,2-dipalmitoyl-sn-glycero-3-
Phosphatidylcholine (egg, chicken); DC8,9PC, (1,2 bi
glycero-3-phosphocholine); DSPE-PEG2000 (18:0 PEG2 P
3 Phosphoethanolamine-N-[Methoxy(Polyethylene gly
HEPES buffer (HBS), 10 mM HEPES, 140 mM NaCl (pH 7.
KH2PO4, 138 mM NaCl, 8.06 mM Na2HPO4-7H2O (pH 7.1
⁎ Corresponding author. Membrane Structure and F
Frederick, NIH, USA. Tel.: +1 301 846 5069; fax: +1 30
E-mail address: apuri@helix.nih.gov (A. Puri).
0005-2736/$ – see front matter. Published by Elsevier
doi:10.1016/j.bbamem.2010.07.030a b s t r a c ta r t i c l e i n f oArticle history:
Received 7 April 2010
Received in revised form 20 July 2010
Accepted 27 July 2010
Available online 4 August 2010
Keywords:
Polymerizable lipids
Laser
Triggered drug release
Diacetylene phospholipid
Radiation-sensitive liposome
Lipid modiﬁcationSuccess of nanoparticle-mediated drug delivery is subject to development of optimal drug release strategies
within deﬁned space and time (triggered release). Recently, we reported a novel class of photo-triggerable
liposomes prepared from dipalmitoyl phosphatidylcholine (DPPC) and photopolymerizable diacetylene
phospholipid (DC8,9PC), that efﬁciently released entrapped calcein (a water soluble ﬂuorescent dye) upon
UV (254 nm) treatment. To develop these formulations for in vivo applications, we have examined
phototriggering of these liposomes by visible light, and the effect of released anticancer drugs on cellular
toxicity. Sonicated liposomes containing various ratios of DPPC:DC8,9PC and 4 mol% DSPE-PEG2000 were
loaded with calcein (Ex/Em, 485/517 nm) or a chemotherapy drug, Doxorubicin (DOX, Ex/Em 490/590 nm).
Our initial experiments showed that 514 nm laser treatment of liposomes containing 10 or 20 mol% DC8,9PC
for 1–3 min resulted in signiﬁcant release of calcein. Based on these results, we performed studies with DOX-
loaded liposomes. First, biophysical properties (including liposome size and stability) and DOX encapsulation
efﬁciency of the liposomes were determined. Subsequently, the effect of 514 nm laser on DOX release, and
cellular toxicity by released DOX were examined. Since liposomes using the 86:10:04 mole ratio of DPPC:
DC8,9PC:DSPE-PEG2000, showed highest encapsulation of DOX, these formulations were investigated
further. We report that (i) liposomes retained about 70% of entrapped DOX at 37 °C in the presence of 0–50%
serum. (ii) 514 nm laser treatment resulted in DOX release from liposomes in a wavelength-speciﬁc manner.
(iii) Laser treatment of co-cultures containing DOX-loaded liposomes and cells (Raji and MCF-7) resulted in
at least 2–3 fold improved cell killing as compared to untreated samples. Taken together, the photo-
triggerable liposomes described here may provide a platform for future drug delivery applications. To our
knowledge, this is the ﬁrst report demonstrating improved cell killing following light-triggered release of an
encapsulated anticancer agent from photosensitive liposomes.phosphocholine; Egg PC, L-α-
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Several nano-delivery systems that are amenable to release drugs
at desired sites have been developed since decades. Among these,
intensive research has been conducted using the liposomes as
triggerable drug carriers [1]. Various triggering modalities examined
to date include local hyperthermia, use of metal ions, pH, enzymes
and light (radiation) [2–4].
Electromagnetic radiation-sensitive liposomes present a promising
system and rely on strategically designed phospholipid molecules toinitiate light-induced trigger [5]. The principle(s) of phototriggering
include photopolymerization of lipids [6], photosensitization by
membrane anchored hydrophobic probes [7–10], or photoisomeriza-
tion of photoreactive lipids [11]. However, none of the formulations
developed so far have been successful for in vivo applications
presumably due to the lack of adequate photon energy produced by
the radiation source(s) or inability of radiation sources used topenetrate
into biological tissues [5]. Therefore, alternate methods to develop
liposomes sensitive to tissue-penetrating wavelengths are warranted
for their successful applications in the clinic.
Photo-triggerable liposome formulations containing wavelength-
speciﬁc photosensitizers (primarily lipidic and/or hydrophobic in
nature) in conjunction with photoactivable lipids are also described.
For example, inclusion of the cationic dye, 1,1′-didodecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate (DiI), induces destabilization
of DOPE:SorbPC (3:1) liposomal membranes when radiated at 550 nm
[12]. In another example, researchers have studied light-sensitive
liposomes based on photochemical triggering, such as plasmenylcho-
line activation by a near infra red (NIR) sensitizer. Plasmenylcholine
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as Zn-phthalocyanine, octabutoxyphthalocyanine, and bacterio-chlo-
rophyll-a. These sensitizing agents absorb between 630 and 820 nm
inducing membrane phase changes that leads to phototriggering of
liposomes and release of contents [5]. Although these wavelengths
have the advantage of deeper tissue penetration depth for clinical
therapeutics, dug release experiments were not established [5,13]. An
added asset in developing photo-triggerable nanoparticles is the steady
improvements in laser-technology yielding greater ability to control
laser systems by the light wavelength, intensity, duration and beam
diameter [14].
The photopolymerizable phospholipid, (1,2 bis(tricosa-10,12-
diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC) (Fig. 1A), is a lipid
present in lower organisms with unique bilayer packing-self-
assembly [15]. Due to highly reactive diacetylene groups uniquely
assembled in the lipid bilayer, photopolymerization by UV treatment
results in chains of covalently linked lipid molecules within the
bilayer [16,17]. Diacetylene groups can be photopolymerized by high
energy radiation and are used to monitor high energy radiation
released in case of a dirty bomb attack [18]. Liposomes prepared from
DC8,9PC alone form tube like structures that are not suitable for drug
entrapment; therefore, liposome formulations with lipid mixtures
were used in our studies (Fig. 1B). Biological applications of DC8,9PC
examined thus far include functionalized polymerized vesicles for
vascular targeted molecular imaging [19], candidates for oral vaccine
preparations [20], and DNA delivery [21,22]. However, in situ light-
triggered drug release potential of DC8,9PC liposomes has not been
reported until recently [23].
Recently, we have demonstrated that liposomes derived from
DPPC:DC8,9PC mixture when treated with UV (254 nm) light released
their entrapped contents. Since the observed leakage was selective to
this lipid mixture, we proposed that the unique packing properties of
DC8,9PC in the liposome bilayer were crucial to promote the observed
effect (photopolymerization) [6,16]. In this report, we have extended
our studies to investigate visible light-triggered drug delivery
potential of these liposomes. Our studies show that laser (514 nm)
treatment of DPPC:DC8,9PC liposomes results in the release of
entrapped calcein (Ex/Em, 485/517 nm) but not calcein blue (Ex/Em
360/460 nm) under identical conditions. This observation suggestsFig. 1. Design principle of photo-triggerable liposomes. (A) Chemical structure of DC8,9PC., (
(matrix lipid), DC8,9PC (photo-triggerable lipid), DSPE-PEG2000 (stabilizing lipid) and entra
membrane resulting in release of DOX.that visible light-induced solute leakage from the liposomes shown
here depends on the spectral properties of entrapped solutes. Since
cellular toxicity by liposomal DOX was also enhanced upon laser
treatment, our photo-triggerable liposomes are likely to form the
basis for next-generation of clinically suitable nano-drug delivery
tools.
2. Materials and methods
2.1. Materials
1,2 bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine,
(DC8,9PC) was synthesized at Naval Research Laboratory using
published literature procedure [24]. All other phospholipids were
purchased from Avanti Polar lipids, Inc. (Alabaster, AL, USA). Calcein
and calcein blue were purchased from Fluka-Sigma-Aldrich (St. Louis,
MO, USA). Agarose beads, Bio-Gel A0.5 mwere purchased fromBio-Rad
Laboratories, Richmond, CA, USA. Doxorubicin-hydrochloride (DOX-
HCl) (Bedford Laboratories, Bedford, OH)was obtained through theNIH
Pharmacy, Clinical Center, Bethesda, MD. PD10 columns were from GE
Healthcare Lifesciences (Piscataway, NJ). All other reagents and buffers
were of reagent grade.
2.2. Cell lines
Lymphoblastoid cells derived from a Burkitt lymphoma (Raji, ATCC
CRL-2367) were grown in RPMI media supplemented with 10% fetal
calf serum, 2 mM L-glutamine, 100 U of penicillin/ml, and 100 μg of
streptomycin/ml (GIBCO® Media, Invitrogen, USA). Human breast
adenocarcinoma cell line (MCF7, ATCC HTB-22) received through the
NCI-DCTD Tumor/cell line repository (http://dtp.nci.nih.gov/brances/
btb/tumor-catalog.pdf) , were grown in RPMI media with 10% fetal
calf 2 mM L-glutamine 100 U of penicillin/ml, and 100 μg of strepto-
mycin/ml (GIBCO® Media, Invitrogen, USA).
2.3. Formation of liposomes
Liposomes were prepared using the probe sonication essentially as
described [23]. The following lipid mixtures were used (Table 1):B) A diagram showing various components of DPPC:DC8,9PC liposomes including DPPC
pped DOX (anticancer drug). The cartoon also shows light-induced defects in the lipid
Table 1
Size analysis and efﬁciency of doxorubicin loading of liposomes.
Liposomesa Size distribution/DOX loading
No DOXb 7 °C 25 °C 37 °C
DPPC:DC8,9PC (96:0)
Formulation I
Sizec ➙ 83.46±2 nm 101.2±2 nm 98.14 nm 117.4±4 nm
Liposomal DOXc ➙ N.A. 728 ng 598 ng 666 ng
DPPC:DC8,9PC (86:10)
Formulation II
Sizec ➙ 99.84±4 nm 150.6±6 nm 159.9±6 nm 114.6±6 nm
Liposomal DOXd ➙ N.A. 1036 ng 1335 ng 141 ng
DPPC:DC8,9PC (76:20)
Formulation III
Sizec ➙ 105.3±2 nm 184.4±6 nm 140.4±6 nm 120.2±2 nm
Liposomal DOXd ➙ N.A. 597 ng 538 ng 182 ng
Egg PC:DC8,9PC (86:10)
Formulation IV
Sizec ➙ 98.31±4 nm 101.2±2 nm 98.31±4 nm 98.31±4 nm
Liposomal DOXd ➙ N.A. 2223 ng 1296 ng 720 ng
a All formulations included 4 mol% DSPE-PEG2000.
b Liposomes before loading of DOX.
c Size was measured by DLS and values represent average diameter of the peak S.D. (from at least 3 measurements).
d Liposomal Pi and DOX were measured (Materials and methods section). The DOX values (nanograms) are expressed per nmol Pi.
Table 2
Serum stability of DOX-loaded liposomes at 37 °Ca.
Natural
leakage
in PBSb
DOX leakage (percent of total entrapped DOX)
DPPC:DC8,9PC
Formulation Ic
DPPC:DC8,9PC
Formulation IIc
DPPC:DC8,9PC
Formulation IIIc
Egg PC:DC8,9PC
Formulation IVc
0% FBS 8.26 2.89 6.58 3.59
10% FBS 15.6 20.69 20.87 4.04
25% FBS 20.14 29.59 29.51 2.91
50% FBS 32.02 34.48 30.48 17.97
a Liposomes were incubated for 24 h. DOX leakage was measured as described in
Materials and methods section.
b PBS was supplemented with various concentrations of FBS.
c All formulations included 4 mol% DSPE-PEG2000.
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DSPE-PEG2000 (86:10:04 mol%, Formulation II); DPPC:DC8,9PC:
DSPE-PEG2000 (76:20:04 mol%, Formulation III), and Egg PC:
DC8,9PC:DSPE-PEG2000 (86:10:04 mol%, Formulation IV).
2.3.1. Encapsulation of calcein or calcein blue in liposomes
To encapsulate calcein or calcein blue, lipid ﬁlmwas reconstituted
in HEPES buffer (HBS, 10 mM HEPES, 140 mM NaCl, pH 7.5)
containing self-quenched concentration of calcein or calcein blue
(0.1 M at pH=7.2–7.6). Unilamellar Vesicles were formed by
sonication at 4 °C for 5–10 min (1 min pulses and 1 min rest) using
a Probe Sonicator (W-375 Heat Systems-Ultrasonics, New York,
USA). The sampleswere centrifuged to remove any titaniumparticles
and larger aggregates. Solute-loaded liposomes were separated from
unentrapped calcein (or calcein blue) using size exclusion gel
chromatography column (Bio-Gel A0.5 m, 1×40 cm, 40 ml bed
volume). Eluted liposomes were collected, liposome-rich fractions
were pooled and the total lipid was determined by measuring
inorganic phosphorus (Pi) as described [25,26]. Liposomes were
ﬁltered through a 0.45 μm ﬁlter (Millex-HV 0.45 μm ﬁlter unit,
Millipore Corporation, Billerica, MA) to maintain their sterility.
Solute loading into liposomes was determined by examining a small
aliquot for ﬂuorescence before and after addition of Triton X-100
(TX100, 0.02% ﬁnal concentration). Fluorescence was measured
using a ﬂuorescent micro plate reader (SpectraMax M2, Molecular
Devices, Sunnyvale CA, USA). Filter sets at Ex/Em 490/530 nm were
used for Calcein and sets at Ex/Em 360/460 nm for Calcein blue.
2.3.2. Encapsulation of Doxorubicin in liposomes
To load DOX into liposomes we used (NH4)2SO4 gradient exchange
method [26,27]. Liposomes were prepared in the presence of ammo-
nium sulfate (300 mM, pH 7.5) and were fractionated on a Bio-Gel
A0.5 mcolumnpre-equilibratedwithHBSbuffer. Eluted liposomeswere
collected, liposome-rich fractions were pooled and the total lipid was
determined by measuring inorganic phosphorus (Pi) [25,26]. The
liposomes were incubated immediately with DOX-HCl at various
temperatures for 12–16 h, typically using 1 mg of the drug for 3 mg of
liposomal lipids.
In our initial studies, we used the Bio-Gel A0.5 m column to separate
liposomes from unentrapped (free) DOX. This chromatography column
has a fractionation range of 10,000–500,000 molecular weight and is a
suitable matrix to separate antibodies and small molecules from
liposomes [26,28]. To determine entrapment efﬁciency of DOX into
liposomes, small aliquots from column fractions were diluted in 2 ml
PBS, Triton X-100 (0.02% ﬁnal concentration) was added, and DOX
ﬂuorescence (Ex/Em 485/590 nm) was measured in a Fluorimeter
(FluoroMax 3, HORIBA Jobin Yvon, Edison, NJ, USA). Next, we
determined the suitability of the PD10 column (GE Healthcare, UK) toseparate unentrapped DOX from liposomal DOX. The amounts of
liposome-encapsulated DOX for a given concentration of liposomal Pi
were similar whether the PD10 column or the Bio Gel A0.5 m column
were used, therefore, we continued with PD10 columns in our
subsequent experiments (see below).2.3.3. DOX release assay
To determine serum stability and light-induced leakage of
liposomal DOX (see below), the assay to monitor DOX leakage was
developed as follows: Test samples were fractionated on the PD10
column and 1 ml (×30) fractions were collected. The fractions were
analyzed for DOX ﬂuorescence in the presence of TX100 (see
preceding section). DOX leakage from liposomes was calculated
based on the formula:
Percent DOX leakage =
F Peak IIð Þ×100
F Peak I + Peak IIð Þ
: ðF ¼ flourescenceÞ
The total amount of DOX loaded on the column equaled the sum of
peak I and peak II representing the area of liposome fractions and free
DOX respectively.2.3.4. Liposome stability assay
Stability of liposomes was determined in the presence of PBS
supplemented with different concentrations of heat-inactivated fetal
bovine serum (FBS). Typically 0.5 ml DOX-loaded liposomes were
incubated with the desired concentration of serum or PBS at 37 °C for
24 h. At the end of incubations, liposomes were fractionated on the
PD10 column and DOX release was determined as described in the
preceding section. Speciﬁc conditions are given in Table 2.
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Light-triggered release of entrapped contents from liposomes was
evaluated either upon exposure to UV [23] or visible light.
UV (254 nm) light treatment of the liposomes (typically containing
≈1.5 nmol Pi/μl diluted 1:10 in PBS, in a total volume of 0.2 ml) was
done in the 96-well plates essentially as described [23], using the UV
lamp (UVP, SHORTWAVE ASSEMLY 115 V, 60 Hz).
For visible light treatment, a multiline mode Argon laser (488/
514 nm, Lexel Laser, Inc., Freemont, Upland, CA, USA) was used. The
liposomeswereplaced in anEppendorf tube (pre-cooled)and irradiated
horizontally with a beam of 500 mW and focused on an area of 1 cm2
(166 mW/cm2/min) for 0–7 min [29]. Light-triggered release of
entrapped calcein or calcein blue from liposomes was measured as
above (Section 2.3.1). To monitor light-triggered release of DOX from
liposomes, DOX release assay was used (described in Section 2.3.3).
2.5. Liposome characterization
Size and population distribution of liposomes were determined by
dynamic light scattering (DLS) measurements using a Malvern
instrument (NANO ZS, Malvern Instruments, CA, USA)[28]. For a
typical sizing experiment 20 μl of liposome solution in 500 μl HBS
buffer were placed into a 1.5 ml microcuvette. Each run consisted of 3
measurements of 12 to 20 acquisitions per sample.
2.6. Cellular toxicity assay
The protocol followed for DOX-mediated cellular toxicity (as a result
of light-triggered release of liposomal DOX) is shown in the cartoon
(Fig. 5). We examined two cell systems; suspension cells (Raji, B-
lymphocyte cell line), and adherent cells (MCF-7, a breast cancer cell
line) in these cytotoxicity assays. Various concentrations of DOX-loaded
liposomeswere added to cells in their respective culturemedia in 1.5 ml
Eppendorf tubes and the cell–liposome suspensions were treated with
514 nm laser for 0–5 min. Subsequently, cells were transferred to 96-
well plates (1–5×104 cells per well, triplicate wells per sample) and
incubations were continued for 48 h at 37 °C. DOX-mediated cellular
toxicitywasmeasured using a cell viability kit (Cell Titer-Blue, Promega,
Madison WI USA) at Ex/Em of 560/590 nm using a ﬂuorescent micro
plate reader (SpectraMax M2, Molecular Devices, Sunnyvale CA, USA).
Untreated cells (without light treatment and without liposomes) were
used as positive controls, and the cell viability in these samples was
taken as 100% cell survival. Additional controls (both positive and
negative) used in our cytotoxicity assays included: (i) similar
concentrations of empty liposomes (without DOX) with or without
light treatment; (ii) DOX-loaded liposome–cell suspensions without
light treatment, and (iii) Equivalent concentrations of free DOXwith or
without light treatment.
3. Results and discussion
In our recent studies, we showed that UV treatment of DPPC
liposomes containing various concentrations of DC8,9PC resulted in
photopolymerization of DC8,9PC and release of entrapped calcein [23].
However, application of these liposomes in vivo is subject to
adaptability to light source(s) that are amenable to tissue-penetrating
wavelengths. This study was designed to examine release of
entrapped solutes by visible wavelength (514 nm) as a platform to
further develop these formulations. The results are presented below.
3.1. Light-induced calcein release from liposomes containing a
diacetylene phospholipid
UV(254 nm) triggered calcein release fromDPPC:DC8,9PC liposomes
[23] suggested that the inclusion of DPPC (but not Egg PC) as thematrixlipid was critical for the observed solute release. Calcein release in this
case was preceded by the photopolymerization of DC8,9PC as evidenced
by change in chromogenic properties of DC8,9PC [23]. However, the
experimental conditions thatwere used to observeUV-triggered calcein
release from these liposomes resulted in substantial damage of cultured
cell lines with or without liposomes as expected (data not shown).
To demonstrate that these liposomes may serve as promising
candidates for light-triggered release applications in vivo, we rational-
ized that cell-compatible wavelengths (such as visible or Near Infra Red
(NIR)) in combination with an appropriate photosensitizer are likely to
producemodiﬁcations in the diacetylene groups necessary for release of
entrapped contents [5,30]. Our ﬁrst experiments towards this effort
were designed to establish the ability of visible light source(s) to
promote leakage of liposome-entrapped molecules. Since DPPC:DSPE-
PEG2000 liposomes containing 10 and 20 mol% DC8,9PC are most
suitable with respect to the solute entrapment efﬁciency and stability
(our previous study) [23], we have tested these formulations. We used
calcein as the model drug as it is a widely used liposome-entrapped
aqueous marker for biophysical studies, and is also known to bear
photosensitizing properties [31]. The results presented below describe
the effect of visible light on the kinetics and extent of calcein release
from light-sensitive liposomes.
DPPC liposomes containing0, 10and20 mol%DC8,9PC (Formulations
I, II and III, Table 1) were treated with a 514 nm argon laser for 0–7 min
at 4 °C, and calcein release was measured (Materials and methods
section). Controls included Egg PC:DSPE-PEG2000 liposomes (96:04
mole ratios) or Egg PC:DC8,9PC:DSPE-PEG2000 (Formulation IV,
Table 1). The data presented in Fig. 2A show that signiﬁcant calcein
release (up to 40%of total entrapped) occurred fromFormulations II and
III, within 2–3 min of laser treatment. Prolonged exposures (N5 min)
resulted in maximum calcein release; however, the ﬂuorescence
intensity of the released calcein was compromised by laser-induced
photodynamic effects of the ﬂuorophore (data not shown). In contrast,
liposomes prepared from Egg PC alone or Egg PC: DC8,9PC (Formulation
IV) did not promote any substantial calcein release (only≤5%) under
identical conditions (Fig. 2A) consistent with our UV-triggered release
results [23]. Surprisingly, we did not see an evidence for photopolymer-
ization upon 514 nm laser treatment of Formulations II and III
(unpublished), although calcein release clearly occurred (Fig. 2A).
Therefore, the visible light-induced solute release from these liposomes
occurs via a mechanism unrelated to photopolymerization.
Since calcein release occurs in the absence of photopolymeriza-
tion in laser-treated Formulations II and III, we surmise that the
photosensitizing properties of entrapped calcein may play a role in
destabilizing the liposomes. Therefore, our next experiments were
designed to evaluate the contribution of liposome-entrapped calcein
on photo-induced leakage by testing an alternate ﬂuorescent
marker, calcein blue (Ex/Em 360/460 nm). Calcein blue loaded
liposomes were treated with 514 nm laser as above and the data are
presented in Fig. 2B. Interestingly, treatment of calcein blue loaded
liposomes (Formulations II and III) with 514 nm laser under
identical conditions did not result in any signiﬁcant leakage of
calcein blue above background (Fig. 2B). However, laser treatments
for longer times (4–7 min) resulted in 5–10% release of calcein blue
from Formulations II and III. Taken together (Fig. 2A and B), our
results support the notion that a wavelength-speciﬁc tunable
photosensitizer (calcein in this case) is important for photodest-
abilization of DC8,9PC formulations in the visible wavelength. We are
currently pursuing this hypothesis by examining the nature of
chemical modiﬁcations in DC8,9PC upon laser treatment in the
absence or presence of calcein (work in progress).
The next experiments aimed to evaluate the potential biological
application of our light-sensitive liposomes are described below. This
experimental design includes studies with liposomes loaded with an
anticancer agent DOX in vitro (Section 3.2) and the ability of released
DOX to promote cytotoxicity (Section 3.3).
Fig. 2. Effect of visible light treatment on release of liposome-entrapped calcein. Calcein-loaded liposomes were prepared from DPPC or Egg PC (as matrix lipids) and 0–20 mol% of
DC8,9PC. All formulations included 4 mol% DSPE-PEG2000. The liposomes were treated with 514 nm laser (0–7 min) and calcein release was measured. Kinetics and extents of light-
induced Calcein (A) and Calcein blue (B) release from liposomes are presented and the numbers represent fraction of calcein released from liposomes taking liposomes treated with
TX100 as 100% total calcein. The data are reproducible from at least three independent experiments.
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For the last several decades, DOX has been used as a key
chemotherapy component in the treatment of various cancers [32].
Side effects associated with DOX, including irreversible cardio-toxicity,
have led to investigations into approaches for drug carriers to achieve
better therapeutic index of DOX. Liposome formulations are well-
studied examples as therapeutic tools for DOX delivery in a variety of
cancer treatments [33,34]. DOX-loaded liposome formulations, (such as
Doxil [35]) are known to improve liposome stability and prolong
circulation time in vivo, but they lack the ability to release entrapped
drugs within deﬁned space and time. Light-triggered release of
liposomal ﬂuorescent molecules (either encapsulated in the aqueous
compartment or incorporated into the lipid counterpart) has been
reported previously [2,5], however, no data is available on the release of
liposome-encapsulated therapeutic drugs in response to light. Here we
have used DOX as a model anticancer agent to demonstrate the
feasibility of DPPC:DC8,9PC liposomes for light-triggered drug delivery.
The following section includes results on DOX encapsulation efﬁciency
(Section3.2.1), stability ofDOX-loaded liposomes (Section3.2.2), visible
light-mediated release of DOX from liposomes (Section 3.2.3), and the
effect of DOX on cytotoxicity following light-triggered release from
liposomes (Section 3.3).
3.2.1. Entrapment efﬁciency of doxorubicin into DPPC:DC8,9PC liposomes
It is evident that optimal drug loading in the liposome
formulations is an important parameter for successful in vivo
applications. Our DOX loading protocol is based on the well-
established ammonium sulfate gradient assay that has proven to
be a viable method for achieving payload of weak bases such as
DOX in the liposomes [27]. We examined efﬁciency of DOX
loading using various lipid formulations at 7, 25 and 37 °C for 12–
16 h. Concurrently, the effect of DOX loading on average size
distribution was also determined (Materials and methods section).
The results are presented in Table 1. Quantitation of liposomal
DOX was done by measuring ﬂuorescence (Materials and methods
section) [26] and the values are presented as ng/nmol phospho-
lipid (determined by inorganic phosphorus (Pi) analysis [25], data
not shown).Our results show that DPPC liposomes (Formulation I) entrapped
≈500–700 ng DOX/nmol phospholipid. The incubations at various
temperatures did not have a signiﬁcant effect on DOX loading for
Formulation I (Table 1). However, DPPC:DC8,9PC:DSPE-PEG2000
liposomes (Formulation II) loaded maximum concentration of DOX
at 25 °C (≈1300 ng/nmol Pi) , while loading efﬁciency was dramat-
ically reduced at 37 °C (≈140 ng/nmol Pi) (Table 1). Similarly, DOX
loading for Formulation III (Table 1) was also optimal at 7 °C or 25 °C
(≈500 ng/nmol Pi), and was signiﬁcantly decreased at 37 °C (180 ng/
nmol Pi). The efﬁciency of DOX loading was at a given temperature
optimal for Formulation II as compared to that of Formulation III.
Therefore, we used Formulation II in our cytotoxicity assays (see
below Section 3.3). Formulation IV (containing Egg PC) showed
maximum loading at 7 °C, presumably due to the lower phase
transition temperature of Egg PC [36]. It is also evident from
Table 1, that there was a slight increase in average size distribution
of DPPC liposomes (Formulation I), whereas DPPC:DC8,9PC liposomes
(Formulations II and III) showed approximately 1.5 fold increase in
size following loading of DOX. In contrast, we did not observe such an
effect on the size distribution of Egg PC:DC8,9PC liposomes (Formu-
lation IV) after DOX loading (Table 1). A detailed analysis of the
morphological parameters is needed to understand this effect.
3.2.2. Stability of DOX-loaded DPPC:DC8,9PC liposomes in serum
Liposomes are known to interact with serum components and
hence destabilize the lipid bilayer [37,38] limiting their successful
application as drug delivery vehicles in vivo [39,40]. Therefore, we
tested the DOX leakage from the liposomes at various concentrations
of serum in PBS for 24 h at 37 °C. The formulations that entrapped
highest DOX (see Table 1) were used for stability experiments.
Although the DOX-loaded liposomes remained stable at 25 °C for
21 days (data not shown), DOX leakage occurred in the presence of
serum at 37 °C. Results are presented in Table 2. We observed only a
slight increase in DOX release above original background in the
absence of FBS at 37 °C for all formulations tested (Table 2).
Incubations in the presence of FBS at 37 °C showed an effect on the
release DOX from liposomes. As expected, increase in serum
concentration from 0 to 50% resulted in more pronounced DOX
release from liposomes. We found that ≈70% DOX remained
Fig. 3. Effect of UV or visible light treatment on release of liposomal Doxorubicin. DOX-
loaded liposomes were prepared from DPPC or Egg PC (as matrix lipids) and 0–20 mol%
of DC8,9PC. All formulations included 4 mol% DSPE-PEG2000. Liposomes were either
treated with UV or visible light and leakage of entrapped DOX was measured after
separation of liposomes from free DOX on a PD10 column (Materials and methods
section). A. DOX release by UV treatment (254 nm, 30 min): (♦) Formulation I (DPPC:
DC8,9PC (96:0); (□), Formulation II (DPPC:DC8,9PC (86:10)); (▲) Formulation III
(DPPC:DC8,9PC (76:20)); (○) Formulation IV (Egg PC:DC8,9PC (86:10)). Inset shows
the percent of DOX leakage calculated as the ratio of peak II (representing free/leaked
DOX) divided by total DOX (the sum of peak I, representing the liposome fractions and
peak II, representing free/leaked DOX). B. DOX release by laser treatment (514 nm,
5 min): (♦)Formulation I (DPPC:DC8,9PC ((96:0)); (□) Formulation II (DPPC:DC8,9PC
(86:10)); (○) Formulation IV (Egg PC:DC8,9PC (86:10)). Inset shows the percent of DOX
leakage calculated as the ratio of peak II (representing free/leaked DOX) divided by
total DOX (the sum of peak I, representing the liposome fractions and peak II,
representing free/leaked DOX). Data were reproducible from at least two independent
experiments.
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(a concentration that mimics serum concentration in vivo). The
Formulation IV (Egg PC) showed ≈80% DOX associated with the
liposomes under similar conditions. Therefore, our liposomes serve as
candidates for the proof of principle experiments to validate our
proposed light-triggered drug delivery technology (described below,
see Sections 3.2.3 and 3.3).
3.2.3. Light-induced leakage of entrapped Doxorubicin from
DPPC:DC8,9PC liposomes
We have previously demonstrated that UV (254 nm)-induced
release of entrapped solutes [23] from DPPC:DC8,9PC liposomes
occurs via the photopolymerization reaction of DC8,9PC molecules in
the lipid bilayer. UV-triggered release is not dictated by physical and
chemical properties of entrapped molecules. In contrast, visible light
(514 nm)-triggered release of calcein (this study) from these
liposomes occurs via an alternate mechanism (unrelated to photo-
polymerization) and depends on the properties of entrapped
molecules (Fig. 2A, calcein, Fig. 2B, calcein blue). Based on these
observations, DOX (Ex/Em 490/590 nm) that possesses photoreac-
tive properties can serve as a suitable model drug for these studies.
First, it was important to establish that phototriggering of DPPC:
DC8,9PC liposomes resulted in release of liposomal DOX, similar to the
observed release calcein.
DOX-loaded liposomes were treated with either 514 or 254 nm
and effects of these treatments on release of DOX were monitored
(Fig. 3 A and B). Liposome-associated DOX was separated from free
DOX on a PD10 column (Materials and methods section). DOX
ﬂuorescence in peak I (liposomes) and peak II (free DOX) was
assayed (Materials and methods section), and total DOX for a given
sample equaled to the sum of peaks I and II. We also calculated the
extent of DOX release for a given sample (shown in insets Fig. 3 A and
B), and the values are presented as percent of total DOX per sample
where higher numbers indicate a higher amount of free DOX.
After UV treatment the extent of DOX release from liposomes was
as follows: ≈20% (Formulation II), and ≈40% (Formulation III) and
≈4% (Formulation I) suggesting that our formulation may be useful
for treatment of cancer (Fig. 3A). These results are consistent with
our previously published calcein release data [23]. We have
previously demonstrated that UV-triggered release of calcein was
speciﬁc to DPPC:DC8,9PC formulations, and replacement of DPPC by
Egg PC in these liposomes obliterated this effect that correlated with
lack of photopolymerization [23]. To validate speciﬁcity of UV-
mediated DOX release from DPPC:DC8,9PC liposomes, we performed
similar studies with Egg PC:DC8,9PC liposomes. After UV treatment of
Egg PC liposomes containing 10 mol%DC8,9PC (Formulation IV),
majority of DOX remained associated with the liposome fraction
(≈4%DOX released). Hence the effect of UV treatmentwas speciﬁc to
DPPC:DC8,9PC formulations (Fig. 3A, Inset). Formulation III showed
higher DOX release upon UV treatment when compared with
Formulation II. However, the amount of DOX encapsulated in
Formulation II was signiﬁcantly higher (≈1300 ng/nmol Pi) in
comparison to Formulation III (≈500 ng/nmol Pi) (Table 1). There-
fore, we focused on Formulation II for our further studies (see below
514 nm laser-induced leakage and subsequent cell toxicity
experiments).
Next, we examined the effect of 514 nm laser on release of DOX
from DPPC:DC8,9PC liposomes. The results presented in Fig. 3B
showed similarity to the UV-mediated effect. We observed a
signiﬁcant increase in DOX release from 514 nm-treated Formulation
II (≈22%) (Fig. 3B, Inset). Under identical conditions, Formulations I
and Formulation IV showed only a slight DOX release (≈8% and 7%
respectively, Fig. 3B, Inset), consistent with lack of calcein release
from liposomes that do not contain DC8,9PC (Fig. 2A). Although visible
light-induced release of ﬂuorescent molecules from photo-triggerable
liposomes have been reported earlier, release of a drug (such as DOXshown in this study) in response to visible light is not shown
previously until this report.
3.3. Visible light treatment increases efﬁciency of cell killing by liposomal
Doxorubicin
To evaluate the drug delivery potential of our liposomes, we
examined the effect of phototriggering on DOX-mediated cellular
toxicity using a variety of cell lines.
Ourﬁrst experiments in this serieswere conductedusingRaji cells (a
B-lymphocyte cell line). In a typical experiment, various concentrations
of Formulation II (see Table 1) were mixed with Raji cells (5×104 per
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laser for 5 min. Subsequently the cell viability (cell survival) was
measured 48 h post-incubations at 37 °C (Materials and methods
section). These incubation conditions were selected because we did
not observe any non-speciﬁc effects of the laser on cell viability in the
absence of DOX and/or liposomes (not shown). Moreover, 5 min
treatments with the laser resulted in optimal DOX release from the
liposomes (Fig. 3B). Results presented in Table 3, show that the laser
treatment in co-cultures of Formulation II with Raji cells reduced cell
survival by 40–60%, and the extents were dependent on the initial input
of liposomes.
Lower doses of liposomal DOX (80 ng, Formulation II) did not affect
the viability of cells in the absence of laser treatment. However, the cell
viability was reduced in laser-treated samples at this concentration
(64% cell survival, Table 3). When higher concentrations of liposomal
DOX were used (160 and 200 ng, Formulation II) in these experiments,
we observed a 20–30% reduction in cell viability in the absence of laser
treatment. Laser treatment of these samples (160 and 200 ng) resulted
in a further reduction in cell viability (≈50% cell survival, Table 3). To
determine the non-speciﬁc effects mediated by liposomal lipids at the
higher concentrations (unrelated to DOX-mediated cell killing), we
incubated equivalent amounts of empty liposomes (not loaded with
DOX) and examined cell viability before and after laser treatment. We
did not observe any effect of lipids on cell viability at all the doses tested
(data are only shown for laser-treated samples, Table 3).
As Formulation IV (containing Egg PC as the matrix lipid) did not
promote a signiﬁcant DOX release upon treatment with 514-nm laser
(Fig. 3B), we used this formulation as an additional control in our cell
survival experiments. We did not see any decrease in cell survival
when Formulation IV was used (with or without laser treatment) up
to 160 ng liposomal DOX (Table 3). At highest dose (200 ng), there
was only a slight decrease in cell viability (5–10%). Furthermore, laser
pretreatment in these samples did not improve cell killing, conﬁrming
the effects seen for Formulation II were mediated by released DOX
following laser treatment. In the absence of laser treatment, slight
reduction in cell survival at high doses of Formulation II corroborates
with our DOX leakage data in the presence of serum (Table 2). For
example, the incubation of Raji cells with Formulation II (160 ng)
reduced cell survival to 80% whereas at the same concentration of
Formulation IV we did not observe any signiﬁcant reduction (97% cell
survival). We attribute this effect to the natural leakage of DOX from
Formulation II (≈20%) as compared to only slight leakage of DOX
from Formulation IV (≈4%).
We also examined the effect of laser treatment on improved cell
killing by liposomal DOX using another suspension cell line, Sup-T1 (T
lymphocytes) and obtained similar results (data not shown).Table 3
Effect of 514 nm laser treatment on liposomal DOX-mediated cytotoxicity.
Liposomes Light
treatment
Cell survival (% of control)a
80b 160b 200b
Formulation II,
DPPC:DC8,9PC
(86:10)
None 99.5±8.5 83.33±10.5 70.46±10.5
Laser 64.26±12.68 51.21±13.1 49.26±12.68
Laserc 100.17±5.5 99.1.12±5.5 101.12±5.5
Formulation IV,
Egg PC:DC8,9PC
(86:10)
None 101.04±2.3 97.35±8.6 93.04±7.5
Laser 104.56±11.5 94.22±8.4 80.59±10.5
Laserc 102.77±6.2 100.97±1.5 105.57±6.2
a Raji cells and liposomes were mixed, treated with 514 nm laser (5 min),
subsequently incubated for 48 h at 37 °C and cell survival was measured (Materials
and methods section). Controls included cell–liposome mixtures without laser
treatment or empty liposome–cell suspensions treated with laser under identical
conditions. The data are expressed as percent cell survival as compared to the cell
viability of cells (without liposomes and without laser treatment) as 100%. The values
are expressed as ±SD from triplicate samples within a single experiment. The results
were reproducible from at least three independent experiments.
b Nanogram liposomal Doxorubicin added per sample.
c Empty liposomes (without any DOX loading).Although we have established that DPPC;DC8,9PC formulations are
viable photo-triggerable drug delivery carriers for suspension cells,
(preceding experiments, this section) we wished to determine if
improved cell killing by laser treatment could be applied to other
cancer cell lines, that are adherent in nature. The similar experiments
were performed using MCF7 cells (breast cancer epithelial cells), and
the results are presented below.
Co-cultures of MCF7 cells (1×104 per sample) and Formulation II
(see Table 1,) were treated with 514 laser as above. Following the laser
treatment, the cell–liposome suspensions were plated on 96-well
clusters (see Materials and methods section), and incubations were
continued for 48 h at 37 °C. The cytotoxicity was determined, and
results are presented in Fig. 4 (A–C). The values are presented as % cell
survival taking MCF-7 cells alone as 100%. First data set (Fig. 4A) shows
results on our control experiment to establish any non-speciﬁc effects of
laser and/or liposomal lipids on the viability ofMCF7 cells. Incubation of
empty liposomes (without DOX) at the corresponding highest dose of
liposomal lipids (≈0.12 nmol Pi/sample) did not result in any cellular
toxicitywith orwithout laser treatment. Therefore, the total lipid and/or
laser treatments per se did not cause any non-speciﬁc effects on cell
viability. In addition, therewasnoeffect of laser treatmentonviability of
MCF7 cells in the absence of liposomes (data not shown). Fig. 4B shows
that the incubation of Formulation II at lower DOX concentration (80 ng
DOX per sample)withMCF7 cells did not reduce cell viability. However,
when the samples were treated with laser (in paired experiments), we
observed a noticeable reduction in cell survival (40%of controls, Fig. 4B),
suggesting thatDPPC:DC8,9PC liposomes are likely to be valid candidates
for light-triggered drug delivery. In our next experiments, we incubated
liposomes with MCF7 cells at high DOX dose (160 ng DOX per sample).
We observed 40% cell killing in samples incubated with DOX-loaded
Formulation II, without laser treatment (Fig. 4C). Pretreatment ofMCF7/
Formulation II suspension with the laser led to a further signiﬁcant
decrease in cell viability (90% cell killing, Fig. 4C). Therefore photo-
triggering of DPPC:DC8,9PC formulations improves cell killing due to the
release ofDOX in the incubationmedium, for a variety of target cell lines
(Raji or MCF7). Our drug delivery carriers described here are likely to
have implications for treatment of multiple tumor types. The observed
cytotoxicity at high doses of Formulation II (in the absence of
phototriggering)was due to natural leakage of DOX from the liposomes.
Therefore, it is critical tomodify liposomes (without compromising their
light-sensitivity) for in vivo applications. Our future studies are aimed at
developing stable liposomes adaptable to in vivo light-triggered drug
delivery (work in progress).
Previous studies show that free DOX is prone to photodynamic
damagewhen exposed to laser, and intracellular accumulation of DOX
minimizes this photo-induced damage [30,41]. Therefore, it was
important to examine the biological activity of free DOX in our
experimental set up. Initially, we optimized the dose of free DOX for
killing of MCF7 cells; 500 ng DOX was sufﬁcient to kill N95% of the
cells, and, therefore this concentration was used for our experiments
(not shown). Free DOX was added to MCF7 cells, the samples were
treated with 514 nm laser, incubated at 37 °C for 48 h, and cellular
toxicity was determined. The results are presented in Fig. 4D.
Incubation of MCF7 cells with free DOX resulted in N95% cytotoxicty
as expected. When the samples were pretreated with laser, the
cytotoxic effect of free DOX was substantially decreased (40% cell
survival). We attribute this effect to the photodynamic damage of free
DOX upon laser treatment. In contrast, DOX encapsulation into
liposomes minimizes the direct photo-induced damage on DOX
[30,41], suggesting that our formulation may have an advantage for
cancer treatment.
Visible light-triggered release of liposome-entrapped contents has
been reported using the light-sensitive formulations including various
photo-triggerable lipids [1,5]. Although calcein has been extensively
used as an aqueous model solute, light-induced activation was also
achieved by lipophilic photosensitizers. Nonetheless, the most of the
Fig. 4. Effect of 514 nm laser treatment on liposomal DOX-mediated cytotoxicty of MCF7 cells. MCF7 cells were harvested using the cell-dissociation buffer and mixed with DOX-
loaded liposomes (Formulation II), treated with laser for 5 min and the cell–liposome mixtures were transferred to 96-well plates (1×104 cells/well in triplicate). Cell toxicity was
measured 48 h post-incubations at 37 °C using the Cell Titer-Blue assay (Materials and methods section). Control samples included cells without liposomes or cell/liposome
suspension without laser treatment. Values are presented as cell survival taking the cell viability of untreated cells as 100% cell survival. ±S.D. represents average of three samples
within a single experiment. A: Empty liposomes (without DOX) corresponding to the 0.12 nmol liposomal Pi per well. B: DOX-loaded liposomes (Formulation II) at 80 ng liposomal
DOX (containing 0.06 nmol Pi) per well. C: DOX-loaded liposomes (Formulation II) at 160 ng liposomal DOX (containing 0.12 nmol Pi) per well. D: Effect of Laser treatment on
efﬁciency of cell killing by free Doxorubicin. Free DOX was added to MCF7 cells to a ﬁnal concentration of 500 ng/well and the samples were treated with laser for 7 min. Controls
were without liposomes or without laser treatment.
Fig. 5. A Schematic representation of a proposed mechanism of laser-triggered release of entrapped solutes from liposomes. Light treatment of DOX-loaded DPPC:DC8,9PC liposomes
results in release of DOX. The effective concentration of the free drug is increased in the vicinity of cells. DOX is subsequently taken up by the cells by passive diffusion leading to
improved cell killing.
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vitro assays. Here, for the ﬁrst time, we have used DC8,9PC for
phototriggering, and to our knowledge, this is the ﬁrst report to
demonstrate light-triggered release of an anticancer agent (DOX) and
the effect of released drug on the biological activity of cells. Moreover,
our formulations are based on photosensitizing properties of
molecules that are entrapped in the aqueous core and not in the
lipidic environment. Hence DPPC:DC8,9PC liposomes are likely to be
suitable in vivo drug delivery applications for multiple drugs
candidates provided the drug can be encapsulated into liposomes at
high concentrations. Further work is being performed in our lab to
characterize the visible light-triggered chemical reactions that result
in destabilization of DPPC:DC8,9PC liposomes.
Use of visible light sources, such as a laser, could be apowerful tool to
improve release of encapsulated drugs from liposomes with minimal
tissue damage. It has been proposed earlier that use of a laser source
matched to the absorption spectrum of DOX can create photoactivation
that will electronically excite molecules and increase cytotoxicity
[30,41]. Published data showed that Argon ion laser radiation at 488
or 514 nm can photoactivate intracellular free DOX and dramatically
increase DOX cytotoxicity in L929 cells. Our results (Table 3, Figs. 4 and
5) are in agreement with the literature ﬁndings that photo-induced
damage will be reduced when DOX is its encapsulated form.
Light-regulated drug delivery has become a useful therapeutic tool
with our enhanced understanding of the photo-regulation and the
properties of photoactivated materials. Treatments based on the UV-
triggered release are restricted to the areas such as skin or mucosa [5],
due to restriction in deep tissue penetration of UV light. Near infra red
light wavelengths penetrate through tissues without damaging DNA
[42]. Therefore, NIR photosensitizers may ﬁnd applications as external
drug delivery devices and as imaging tools in animal models [14].4. Concluding remarks
An important requirement for effective drug delivery is the precise
spatial and temporal release of therapeutic agents at the target site.
Development of nano-carriers with triggered release mechanism(s)
will reduce potential toxicity and lead to more effective therapy. To
date, various photo-triggerable liposome formulations are described
in literature as candidates for localized drug delivery. However, none
of these studies have demonstrated light-triggered delivery of
cytotoxic agents to improve cell killing.
The focus of the present work was to demonstrate that light-
triggered release of an anticancer agent (DOX) from light-sensitive
liposomes (containing the photosensitive phospholipid DC8,9PC)
promotes cell killing. The model presented in Fig. 5 summarizes the
advantages of light-triggerable drug delivery vehicles for cancer
therapeutics. Although nanoparticles are preferentially taken up by
the leaky vasculature of tumors, we are improving liposome binding
by developing DPPC:DC8,9PC liposomes formulations that include
agents for speciﬁc targeting to tumor cells. The triggerable liposomes
described here also bear the potential to adapt to electromagnetic
radiations (such as X-rays or NIR) lasers for future in vivo
applications.Acknowledgements
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